enVVeno Medical Corporation
Update in progressNVNO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
enVVeno Medical Corporation is a medical device company focused on bioprosthetic tissue–based solutions for venous disease. Its lead product, VenoValve, is a surgical replacement valve for chronic venous insufficiency and is implanted in the femoral vein during open surgery via a thigh incision. The company is also developing enVVe, a transcatheter venous valve system. Formerly Hancock Jaffe Laboratories, it was renamed in 2021 and is based in Irvine, California.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.04
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section